Abstract
Based on the good results of experimental transplantation in animal models of multiple sclerosis and of other autoimmune diseases, we have treated 24 patients suffering from chronic progressive multiple sclerosis with high-dose chemotherapy (BEAM regimen) followed by autologous blood stem cell rescue and antithymocyte globulin. Blood stem cells were mobilised with cyclophosphamide at 4g/m2 and G- (or GM-) CSF. In 9 cases, additional CD34+ cell-selection of the graft was performed. Here we update previously published results of this novel treatment, mainly with regard to clinical efficacy, as the median follow-up time has reached 40 months (range, 21–51). Infections were the principal toxicity early after the procedure, with death of a patient from aspergillosis 65 days post stem cell infusion. No serious late events occurred apart from a case of autoimmune thyroiditis that developed 11 months after transplant in a patient who had received a CD34+ cell-depleted graft. Mild and transient neurotoxicity was observed in 10 patients (42%), most probably associated with fever and infections. Eighteen patients (18/23; 78%) responded to the treatment, i.e., they were improved or stabilized, while five patients progressed, of which 4 had primary progressive disease. Of those improved or stabilised (18), 9 patients have maintained stable condition whereas 9 developed relapses or they slowly resumed progression, although their disability scores have not gotten worse than they were before transplantation. The probability of progression-free survival (compared to entry status) at 3 years is 92% for patients with secondary progressive disease and 39% for the primary progressive type. CD34+ cell-selection did not seem to yield better results except for a delay in progression or in relapse after transplantation. These results appear better than those achieved by any other treatment of progressive multiple sclerosis, including beta-interferon, but they need to be confirmed by other open or controlled studies in view of the well-known difficulty of judging objectively the effect of a treatment in patients with this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Gulcher JR, Vartanian T, Stefansson K: Is multiple sclerosis an autoimmune disease? Clin Neurosci 2:246-252, 1994
Hohlfeld R, Londi M, Massacesi L, Salvetti M: T-cell immunity in multiple sclerosis. Immunol Today 16:259-261, 1995
Snowden JA, Brooks PM, Biggs JC: Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol 99:9-22, 1997
Matthews WB: Course and prognosis. In McAlpine's Multiple Sclerosis, WB Matthews, A Compston, IV Allen, CN Martyn (eds). Singapore, Churchill Livingstone, 1991, pp. 139-163
Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM: Management of multiple sclerosis. New Engl J Med 337:1604-1611, 1997
Marmont AM, van Bekkum DW: Stem cell transplantation for severe autoimmune diseases. Bone Marrow Transplant 16:497-498, 1995
Marmont AM: Stem cell transplantation for severe autoimmune diseases: Progress and problems. Haematologica 83:733-743, 1998
van Bekkum DW, Marmont AM, Tyndall A, Vriesendorp FJ, Apatoff BJ, Rowlings PA: Severe autoimmune diseases: A new target for bone marrow transplantation. Stem cells 14:460-472, 1996
McAllister LD, Beatty PG, Rose J: Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant 19:395-397, 1997
Apatoff BR: Stem cell transplantation in the treatment of multiple sclerosis. Stem Cells 14:467-472, 1996
van Gelder M, van Bekkum DW: Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant 18: 1029-1034, 1996
van Bekkum DW: New opportunities for the treatment of severe autoimmune diseases: Bone marrow transplantation. Clin Immunol Immunopathol 89:1-10, 1998
Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O, Slavin S: Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 92:765-772, 1993
Fassas A, Anagnostopoulos A, Kazis A, Kapinas A, Sakellari I, Kimiskidis V, Tsompanakou A: Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: First results of a pilot study. Bone Marrow Transplant 20:631-638, 1997
Fassas A, Anagnostopoulos A, Kazis A, Kapinas K, Sakellari I, Kimiskidis V, Yannaki E: Autologous blood stem cell therapy for progressive multiple sclerosis. In Autologous Blood and Marrow Transplantation—Proceedings of the Ninth International Symposium, Arlington, Texas, KA Dicke, A Keating (eds). Charlottesville, Carden Jennings, 1999, pp 452-463
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452, 1983
Tyndall A, Gratwohl A: Blood and marrow stem cell transplants in autoimmune disease: A consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow transplantation (EBMT). Bone Marrow Transplant 19:643-645, 1997
Comi G, Kappos L, Clanet M, Ebers G, Fassas A, Fazekas F, Filippi M, Hartung HP, Martino G, Tyndall A, van der Meche FGA, BMT-MS Study Group: guidelines for blood and marrow stem cell transplantation in multiple sclerosis. J Neurology (in press)
Weinshenker G, Issa M, Baskerville J: Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology 46:1613-1619, 1996
European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497, 1998
Slavin S, Karussis D, Weiss L, Vourka-Karoussis U, Abramsky O: Immunohematopoietic reconstitution by allogeneic and autologous bone marrow grafts as a means for induction of specific unresponsiveness to donor-specific allografts and modified self in autoimmune disorders. Transplant Proc 25:1274-1275, 1993
Snowden JA, Brooks PM: Hematopoietic stem cell transplantation in rheumatic diseases. Current Opinion Rheumatol 11:167-172, 1999
Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, Terry C, Lobeck L, Russel EJ, Goolsby C, Rosen S, Gordon LI, Keever-Taylor C, Brush M, Fishman M, Burns WH: T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 21:537-541, 1998
Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH: Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 92:3505-3514, 1998
Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ: Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 129:1031-1035, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fassas, A., Anagnostopoulos, A., Kazis, A. et al. Autologous Stem Cell Transplantation in Progressive Multiple Sclerosis—An Interim Analysis of Efficacy. J Clin Immunol 20, 24–30 (2000). https://doi.org/10.1023/A:1006686426090
Issue Date:
DOI: https://doi.org/10.1023/A:1006686426090